• 1. Examination of the hydrogen-bonding networks in small water clusters (n = 2–5, 13, 17) using absolutely localized molecular orbital energy decomposition analysis?
  Erika A. Cobar,Paul R. Horn,Robert G. Bergman,Martin Head-Gordon Phys. Chem. Chem. Phys., 2012,14, 15328-15339
• 2. Esterase-responsive polymeric prodrug-based tumor targeting nanoparticles for improved anti-tumor performance against colon cancer?
  Gang Pan,Yi-jie Bao,Jie Xu,Tao Liu,Cheng Liu,Yan-yan Qiu,Xiao-jing Shi,Hui Yu,Ting-ting Jia,Xia Yuan,Ze-ting Yuan,Yi-jun Cao RSC Adv., 2016,6, 42109-42119
• 3. Establishing empirical design rules of nucleic acid templates for the synthesis of silver nanoclusters with tunable photoluminescence and functionalities towards targeted bioimaging applications?
  Jason Y. C. Lim,Yong Yu,Guorui Jin,Kai Li,Yi Lu,Jianping Xie Nanoscale Adv., 2020,2, 3921-3932
• 4. Essential effect of the electrolyte on the mechanical and chemical degradation of LiNi0.8Co0.15Al0.05O2 cathodes upon long-term cycling??
  Xiaoming Liu,Zachary D. Hood,Wangda Li,Donovan N. Leonard,Arumugam Manthiram,Miaofang Chi J. Mater. Chem. A, 2021,9, 2111-2119
• 5. Fast-Track to Research Data Management in Experimental Material Science-Setting the Ground for Research Group Level Materials Digitalization.
  LarsBanko,AlfredLudwig

Comprehensive Analysis of Ziprasidone Amino Acid (CAS No. 1159977-64-6): Properties, Applications, and Research Insights

Ziprasidone amino acid (CAS No. 1159977-64-6) is a specialized derivative of the well-known antipsychotic drug ziprasidone. This compound has garnered significant attention in pharmaceutical research due to its potential to enhance drug delivery and bioavailability. The integration of an amino acid moiety into the ziprasidone structure aims to improve solubility and metabolic stability, addressing key challenges in central nervous system (CNS) drug development. Researchers are particularly interested in its role as a prodrug or intermediate in synthesizing advanced therapeutic formulations.

The molecular structure of ziprasidone amino acid combines the pharmacologically active benzisothiazole core of ziprasidone with strategically linked amino acid functional groups. This modification is designed to optimize pharmacokinetic properties while retaining the original compound's affinity for dopamine (D2) and serotonin (5-HT2A) receptors. Current studies focus on its application in schizophrenia treatment, bipolar disorder management, and other neuropsychiatric conditions where improved blood-brain barrier penetration is critical.

From a synthetic chemistry perspective, CAS No. 1159977-64-6 represents an innovative approach to drug modification. The introduction of amino acid components facilitates better water solubility compared to the parent compound, potentially reducing the need for complex delivery systems like micelles or liposomes. This aligns with current industry trends toward patient-centric formulations that enhance compliance through simplified administration protocols.

Analytical characterization of ziprasidone amino acid involves advanced techniques such as HPLC-MS and NMR spectroscopy, which confirm both purity and structural integrity. Stability studies under various pH conditions are particularly relevant given the growing emphasis on oral dosage form optimization in psychiatric medications. These investigations contribute valuable data for pharmacokinetic modeling and dose-response prediction in preclinical development.

The therapeutic potential of this derivative intersects with several trending topics in medicinal chemistry, including precision psychiatry and personalized medicine. Its development reflects the broader shift toward structure-activity relationship (SAR) optimization in CNS drugs, where minor molecular modifications can significantly impact efficacy and safety profiles. Recent patent literature suggests applications in sustained-release formulations and combination therapies for treatment-resistant mental health conditions.

Quality control protocols for CAS No. 1159977-64-6 emphasize rigorous testing for chiral purity, given the stereochemical considerations inherent in amino acid-containing compounds. This aspect is crucial for meeting regulatory standards in major markets like the US FDA and EMA, where enantiomeric control is strictly monitored for psychotropic substances. Manufacturers typically employ asymmetric synthesis or chiral resolution techniques to ensure batch consistency.

Emerging research explores the compound's utility beyond traditional psychiatric applications, including preliminary investigations into neuroprotective mechanisms and glutamate modulation. These directions respond to the increasing scientific interest in multi-target therapeutics for complex neurological disorders. The amino acid component may confer additional benefits in mitochondrial function and oxidative stress reduction, areas gaining traction in neurodegeneration research.

From a commercial standpoint, ziprasidone amino acid occupies a niche but growing segment in the pharmaceutical intermediates market. Its synthesis typically involves peptide coupling methodologies, with process optimization focusing on atom economy and green chemistry principles - key concerns in modern API manufacturing. The compound's patent status and regulatory pathway remain active areas of inquiry for generic drug developers.

Ongoing clinical needs drive innovation around this molecule, particularly regarding reduced side effect profiles in antipsychotic therapies. The amino acid modification may lower risks of QT interval prolongation and metabolic syndrome associated with some atypical antipsychotics. Such advantages align with current treatment guidelines emphasizing long-term safety in chronic mental illness management.

In summary, ziprasidone amino acid (CAS No. 1159977-64-6) exemplifies contemporary strategies in CNS drug design, merging established pharmacology with innovative chemical approaches. Its development trajectory reflects broader trends toward biopharmaceutical optimization and therapeutic targeting, offering promising avenues for improved neuropsychiatric treatments. Future research will likely explore its potential in digital therapeutics integration and biomarker-guided therapy, positioning this compound at the forefront of next-generation psychiatric care.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)